Showing results (451-460 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|December 4, 2016
STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4AShuo Wang, Cedric Darini, Laurent Désaubry, et al.
Molecular Cancer Therapeutics|December 23, 2016
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of MelanomaRaghavendra Gowda, Gregory Kardos, Arati Sharma, et al.
Molecular Cancer Therapeutics|December 2, 2016
A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML CellsYoshinori Ishikawa, Kanae Gamo, Masato Yabuki, et al.
Molecular Cancer Therapeutics|December 14, 2016
Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer CellsEmiliano Cocco, Yang Deng, Erik M Shapiro, et al.
Molecular Cancer Therapeutics|December 17, 2016
The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional GenomicsSanne R Martens-de Kemp, Arjen Brink, Ida H van der Meulen, et al.
Molecular Cancer Therapeutics|December 17, 2016
Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-βElena Jachetti, Alice Rigoni, Lucia Bongiovanni, et al.
Molecular Cancer Therapeutics|December 17, 2016
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent CancersKaiming Sun, Ruzanna Atoyan, Mylissa A Borek, et al.
Molecular Cancer Therapeutics|September 29, 2016
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell GrowthJun Chen, Taisei Kinoshita, Juthamas Sukbuntherng, et al.
Molecular Cancer Therapeutics|February 5, 2008
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cellsElizabeth A Duncan, Christine A Goetz, Sarah J Stein, et al.
Molecular Cancer Therapeutics|February 19, 2008
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrestAime A Levesque, Andrew A Fanous, Alissa Poh, et al.
Pageof 599